Trials / Completed
CompletedNCT05600036
A Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Plaque Psoriasis
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Moderate to Severe Plaque Psoriasis
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 228 (actual)
- Sponsor
- Alumis Inc · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This is a multi-center, randomized, double-blind, placebo-controlled study in patients with moderate to severe plaque psoriasis.
Detailed description
This study will consist of a 4 week screening period, 12 week treatment period, and a 4 week follow up period for a total of 20 weeks. Each participant will be randomized to receive ESK-001 or placebo daily for 12 weeks. An open label extension study will be available for those patients who complete the study.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ESK-001 | Oral tablet |
| DRUG | Placebo | Oral tablet |
Timeline
- Start date
- 2022-09-27
- Primary completion
- 2023-06-29
- Completion
- 2023-07-25
- First posted
- 2022-10-31
- Last updated
- 2025-06-18
- Results posted
- 2024-07-23
Locations
53 sites across 3 countries: United States, Canada, Czechia
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05600036. Inclusion in this directory is not an endorsement.